SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC.

@article{Cappuzzo2009SATURNAD,
  title={SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC.},
  author={Federico Cappuzzo and Tudor Eliade Ciuleanu and Lilia Stelmakh and Saulius Cicėnas and Aleksandra Szczęsna and Erzs{\'e}bet Juh{\'a}sz and Emilio Esteban Gonz{\'a}lez and Olivier Molinier and Ga{\"e}lle Klingelschmitt and Guiseppe Giaccone},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={8001}
}
8001 Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus placebo (P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated to evaluate E as maintenance therapy after standard 1st-line platinum-based chemotherapy (CT) in advanced NSCLC. METHODS Patients with no evidence of disease progression after 4 cycles of CT were randomized to receive either E 150 mg/day or P until progression or unacceptable toxicity. The primary endpoint… CONTINUE READING
67 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

Similar Papers

Loading similar papers…